English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Latest Press Releases
Thursday, July 23, 2020
要约人建议透过协议计划方式私有化中国宝丰国际及撤销其上市地位
18:12 HKT/SGT
要約人建議透過協議計劃方式私有化中國寶豐國際及撤銷其上市地位
18:11 HKT/SGT
Proposed Privatisation of China Baofeng (International) Limited by the Offeror by way of a Scheme of Arrangement and Withdrawal of Listing of China Baofeng (International) Limited
18:10 HKT/SGT
Inaugural 'Standard Chartered GBA Business Confidence Index'
18:00 HKT/SGT
Mazda's Future Factory Operation Plans
13:17 HKT/SGT
Greenbriar Comments on Recent Controversy on Social Media
13:00 HKT/SGT
德事商务中心进一步在中国大陆三个地区拓展全球发展足迹
10:02 HKT/SGT
德事商務中心擴展環球足跡至中國三個地區
10:01 HKT/SGT
TEC Expands Global Footprint Across Three Locations in China
10:00 HKT/SGT
国美零售携手央视新闻加速推进本地化零售布局
09:04 HKT/SGT
國美零售攜手央視新聞加速推進本地化零售佈局
09:03 HKT/SGT
银城国际获安信国际首次研报覆盖,评级「买入」并给予目标价2.8港元
09:01 HKT/SGT
銀城國際獲安信國際首次研報覆蓋,評級「買入」並給予目標價2.8港元
09:00 HKT/SGT
中国抗体与D2M建立战略合作关系
07:22 HKT/SGT
中國抗體與D2M建立戰略合作關係
07:21 HKT/SGT
SinoMab entered into Strategic Collaboration with D2M
07:20 HKT/SGT
아방스 클리니컬, 아토사 테라퓨틱스의 두 번째 코로나19 치료제 개발 프로그램인 비강 분무용 치료제 AT-301 임상 연구 계약
06:00 HKT/SGT
Avance Clinical簽約展開Atossa Therapeutics AT-301鼻噴霧劑臨床研究,這是Atossa的第二個新冠肺炎治療開發項目
06:00 HKT/SGT
Avance Clinical签约展开Atossa Therapeutics AT-301鼻喷雾剂临床研究,这是Atossa的第二个新冠肺炎治疗开发项目
06:00 HKT/SGT
Wednesday, July 22, 2020
Benchmark Adds a Fifth Drill Rig at its Gold-Silver Project and Provides Program Update
17:00 HKT/SGT
Dorsett Hospitality International partners with Prenetics to provide government-recognised Covid-19 testing to combat the third wave
17:00 HKT/SGT
Hitachi to Support for Researches on Infectious Diseases through The Hitachi Global Foundation
16:36 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
16:04 HKT/SGT
NEC、画像解析を活用して鉄道の沿線検査業務を支援する「列車巡視支援システム」を実用化
14:00 HKT/SGT
がん研有明病院と日立、「EMIEW」を活用し"新型コロナウイルス感染症流行下における来院者安全確保補助・医療従事者負担軽減効果"の評価研究を開始
14:00 HKT/SGT
LEXUS、「RX」を一部改良
13:30 HKT/SGT
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program
13:00 HKT/SGT
アンケートサイトにて500名に聞く「オンラインカジノ」認知調査。
12:00 HKT/SGT
アンケートサイトにて500名に聞く「オンラインカジノ」認知調査。
12:00 HKT/SGT
Singapore Vet 2021 New Dates
10:05 HKT/SGT
富士通研究所、ミリ波帯ローカル5Gシステムに対応した無線基地局の自動配置計算を高速化
10:00 HKT/SGT
Fujitsu Develops Technology to Optimize Deployment of Millimeter-Wave Private 5G System Base Stations
09:27 HKT/SGT
アルツハイマー病協会国際会議2020(AAIC2020)においてエーザイのアルツハイマー病/認知症領域の開発品に関する最新データを発表
09:00 HKT/SGT
Episode Six社、デジタル変革への実績が評価され、700万米ドルの資金調達によりグローバルな成長を加速
09:00 HKT/SGT
君实生物抗Trop2单抗-Tub196偶联剂JS108获准进入临床试验
08:41 HKT/SGT
Agilex Biolabs and Endpoints News Present 'How to Move Trials to Australia' Webinar
06:00 HKT/SGT
애질렉스 바이오랩스와 엔드포인츠 뉴스, ‘호주로의 임상 시험 이전’ 웨비나 공동개최
06:00 HKT/SGT
Agilex Biolabs和Endpoints News推出“如何將試驗轉移到澳大利亞”網絡研討會
06:00 HKT/SGT
Agilex Biolabs和Endpoints News推出“如何将试验转移到澳大利亚”网络研讨会
06:00 HKT/SGT
Madeline 'Maddy' Cross-Parkin Appointed Director of Music Grants for The Scheer Foundation
04:00 HKT/SGT
Tuesday, July 21, 2020
对游离态尼古丁和冠状病毒的研究表明:事实比我们想象的要复杂得多
22:09 HKT/SGT
對游離態尼古丁和冠狀病毒的研究表明:事實比我們想像的要複雜得多
22:07 HKT/SGT
Reproducing the Driver's Senses by Engineering: DENSO's Challenge to Develop Automated Driving Systems
21:35 HKT/SGT
Episode Six Secures $7 Million to Accelerate Global Growth as Demand for Digital Transformation Increases
21:00 HKT/SGT
現在の経済情勢の中でのPrance Gold Holdingsのデジタルトランスフォーメーション
20:00 HKT/SGT
 ACN Search:
 
The CENTRESTAGE virtual runway shows officially begin today. Combining traditional fashion shows with computer-generated imagery, these unique runway events feature collections from more than 40 Hong Kong and Asian designers.
 
Daily Newsletter
Browse Press Releases
Press Releases by Industry »
Press Releases by Language »
Multimedia Press Releases »
Events newsroom »
 Events:
More events >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575